Ignite Creation Date:
2024-05-05 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00372853
Status:
COMPLETED
Last Update Posted:
2012-06-06
First Post:
2006-09-05
Brief Title:
Dose-Finding Study Of CP-675206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Phase 1 Dose Escalation Trial To Evaluate The Safety And Tolerability Of CP-675206 Administered In Combination With SU011248 To Patients With Metastatic Renal Cell Carcinoma
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will determine the highest tolerable dose of CP-675206 when given in combination with SU011248
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None